Search Results - "Coorey, Craig P"

  • Showing 1 - 7 results of 7
Refine Results
  1. 1

    Long-term nitrogen dioxide exposure assessment using back-extrapolation of satellite-based land-use regression models for Australia by Knibbs, Luke D., Coorey, Craig.P., Bechle, Matthew J., Marshall, Julian D., Hewson, Michael G., Jalaludin, Bin, Morgan, Geoff G., Barnett, Adrian G.

    Published in Environmental research (01-05-2018)
    “…Assessing historical exposure to air pollution in epidemiological studies is often problematic because of limited spatial and temporal measurement coverage…”
    Get full text
    Journal Article
  2. 2
  3. 3

    The hemostatic activity of cryopreserved platelets is mediated by phosphatidylserine-expressing platelets and platelet microparticles by Johnson, Lacey, Coorey, Craig P., Marks, Denese C.

    Published in Transfusion (Philadelphia, Pa.) (01-08-2014)
    “…Background Cryopreservation of platelets (PLTs) at −80°C with dimethyl sulfoxide (DMSO) can extend the shelf life from 5 days to 2 years. Cryopreserved PLTs…”
    Get full text
    Journal Article
  4. 4

    Independent Validation of National Satellite-Based Land-Use Regression Models for Nitrogen Dioxide Using Passive Samplers by Knibbs, Luke D, Coorey, Craig P, Bechle, Matthew J, Cowie, Christine T, Dirgawati, Mila, Heyworth, Jane S, Marks, Guy B, Marshall, Julian D, Morawska, Lidia, Pereira, Gavin, Hewson, Michael G

    Published in Environmental science & technology (15-11-2016)
    “…Including satellite observations of nitrogen dioxide (NO2) in land-use regression (LUR) models can improve their predictive ability, but requires rigorous…”
    Get full text
    Journal Article
  5. 5

    The long-term effects of switching from active intravenous bisphosphonate treatment to low-dose maintenance therapy in children with osteogenesis imperfecta by Biggin, Andrew, Zheng, Linda, Briody, Julie N, Coorey, Craig P, Munns, Craig F

    Published in Hormone research in paediatrics (01-01-2015)
    “…Intravenous bisphosphonate therapy is the first-line treatment in moderate-to-severe osteogenesis imperfecta (OI), but there are varied treatment protocols…”
    Get more information
    Journal Article
  6. 6
  7. 7

    Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors by Figtree, Gemma A., Vernon, Stephen T., Harmer, Jason A., Gray, Michael P., Arnott, Clare, Bachour, Eric, Barsha, Giannie, Brieger, David, Brown, Alex, Celermajer, David S., Channon, Keith M., Chew, Nicholas W.S., Chong, James J.H., Chow, Clara K., Cistulli, Peter A., Ellinor, Patrick T., Grieve, Stuart M., Guzik, Tomasz J., Hagström, Emil, Jenkins, Alicia, Jennings, Garry, Keech, Anthony C., Kott, Katharine A., Kritharides, Leonard, Mamas, Mamas A., Mehran, Roxana, Meikle, Peter J., Natarajan, Pradeep, Negishi, Kazuaki, O’Sullivan, John, Patel, Sanjay, Psaltis, Peter J., Redfern, Julie, Steg, Philippe G., Sullivan, David R., Sundström, Johan, Vogel, Birgit, Wilson, Andrew, Wong, Dennis, Bhatt, Deepak L., Kovacic, Jason C., Nicholls, Stephen J., Ademi, Zanfina, Avis, Suzanne Robyn, Chan, Adam, Contreras, Osvaldo, Coorey, Craig P., Fathieh, Sina, Genetzakis, Elijah, Gholipour, Alireza, Giles, Corey, Hollings, Matthew, Hyun, Karice, Kazi, Samia, Kovacic, Jason C., Larance, Mark, Marathe, Jessica A., Marquina, Clara, Nelson, Adam, Ng, Hooi Hooi, Patrick, Ellis, Peter, Karlheinz, Tran, Andy, Yang, Jean, Zhu, Dantong, Zwack, Clara

    “…Reducing the incidence and prevalence of standard modifiable cardiovascular risk factors (SMuRFs) is critical to tackling the global burden of coronary artery…”
    Get full text
    Journal Article